Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Addington J, Liu L, Chu M, Jungert K, Penzel N, Pasternak O, Farina E, Carrion RE, Corcoran CM, Mittal VA, Strauss GP, Yung AR, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Castillo-Passi RI, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Ellman LM, Poli PF, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mourgues C, Nordentoft M, Nunez AR, Pearlson GD, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, Zhang T, Addamo L, Buccilli K, Dwyer D, Todd S, Cho YT, Fontenau C, Tamayo Z, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW, Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby, Calkins ME

Open source

DOI
10.1093/schizbullopen/sgaf012
Published
2025 Jan
Container
Schizophrenia bulletin open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/schizbullopen/sgaf012,
  title = {Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.},
  author = {Addington J and Liu L and Chu M and Jungert K and Penzel N and Pasternak O and Farina E and Carrion RE and Corcoran CM and Mittal VA and Strauss GP and Yung AR and Alameda L and Arango C and Borders O and Bouix S and Breitborde NJK and Broome MR and Cadenhead KS and Castillo-Passi RI and Chen EYH and Choi J and Coleman MJ and Conus P and Diaz-Caneja CM and Ellman LM and Poli PF and Gaspar PA and Gerber C and Glenthøj LB and Horton LE and Hui CLM and Kambeitz J and Kambeitz-Ilankovic L and Kapur T and Kelly S and Kerr MJ and Keshavan MS and Kim M and Kim SW and Koutsouleris N and Kwon JS and Langbein K and Lewandowski KE and Mamah D and Marcy PJ and Mathalon DH and Mourgues C and Nordentoft M and Nunez AR and Pearlson GD and Perez J and Perkins DO and Powers AR 3rd and Rogers J and Sabb FW and Schiffman J and Seitz-Holland J and Shah JL and Silverstein SM and Smesny S and Stone WS and Thompson JL and Upthegrove R and Verma S and Wang J and Wolf DH and Zhang T and Addamo L and Buccilli K and Dwyer D and Todd S and Cho YT and Fontenau C and Tamayo Z and Bearden CE and Kane JM and McGorry PD and Kahn RS and Shenton ME and Woods SW and Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby and Calkins ME},
  year = {2025},
  journal = {Schizophrenia bulletin open},
  doi = {10.1093/schizbullopen/sgaf012},
  url = {https://doi.org/10.1093/schizbullopen/sgaf012}
}

RIS

TY  - JOUR
TI  - Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.
AU  - Addington J
AU  - Liu L
AU  - Chu M
AU  - Jungert K
AU  - Penzel N
AU  - Pasternak O
AU  - Farina E
AU  - Carrion RE
AU  - Corcoran CM
AU  - Mittal VA
AU  - Strauss GP
AU  - Yung AR
AU  - Alameda L
AU  - Arango C
AU  - Borders O
AU  - Bouix S
AU  - Breitborde NJK
AU  - Broome MR
AU  - Cadenhead KS
AU  - Castillo-Passi RI
AU  - Chen EYH
AU  - Choi J
AU  - Coleman MJ
AU  - Conus P
AU  - Diaz-Caneja CM
AU  - Ellman LM
AU  - Poli PF
AU  - Gaspar PA
AU  - Gerber C
AU  - Glenthøj LB
AU  - Horton LE
AU  - Hui CLM
AU  - Kambeitz J
AU  - Kambeitz-Ilankovic L
AU  - Kapur T
AU  - Kelly S
AU  - Kerr MJ
AU  - Keshavan MS
AU  - Kim M
AU  - Kim SW
AU  - Koutsouleris N
AU  - Kwon JS
AU  - Langbein K
AU  - Lewandowski KE
AU  - Mamah D
AU  - Marcy PJ
AU  - Mathalon DH
AU  - Mourgues C
AU  - Nordentoft M
AU  - Nunez AR
AU  - Pearlson GD
AU  - Perez J
AU  - Perkins DO
AU  - Powers AR 3rd
AU  - Rogers J
AU  - Sabb FW
AU  - Schiffman J
AU  - Seitz-Holland J
AU  - Shah JL
AU  - Silverstein SM
AU  - Smesny S
AU  - Stone WS
AU  - Thompson JL
AU  - Upthegrove R
AU  - Verma S
AU  - Wang J
AU  - Wolf DH
AU  - Zhang T
AU  - Addamo L
AU  - Buccilli K
AU  - Dwyer D
AU  - Todd S
AU  - Cho YT
AU  - Fontenau C
AU  - Tamayo Z
AU  - Bearden CE
AU  - Kane JM
AU  - McGorry PD
AU  - Kahn RS
AU  - Shenton ME
AU  - Woods SW
AU  - Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby
AU  - Calkins ME
PY  - 2025
JO  - Schizophrenia bulletin open
DO  - 10.1093/schizbullopen/sgaf012
UR  - https://doi.org/10.1093/schizbullopen/sgaf012
ER  - 

APA

J, A., L, L., M, C., K, J., N, P., O, P., E, F., RE, C., CM, C., VA, M., GP, S., AR, Y., L, A., C, A., O, B., S, B., NJK, B., MR, B., KS, C., RI, C., EYH, C., J, C., MJ, C., P, C., CM, D., LM, E., PF, P., PA, G., C, G., LB, G., LE, H., CLM, H., J, K., L, K., T, K., S, K., MJ, K., MS, K., M, K., SW, K., N, K., JS, K., K, L., KE, L., D, M., PJ, M., DH, M., C, M., M, N., AR, N., GD, P., J, P., DO, P., 3rd, P. A., J, R., FW, S., J, S., J, S., JL, S., SM, S., S, S., WS, S., JL, T., R, U., S, V., J, W., DH, W., T, Z., L, A., K, B., D, D., S, T., YT, C., C, F., Z, T., CE, B., JM, K., PD, M., RS, K., ME, S., SW, W., Barnaby, A. M. P. S. N., & ME, C. (2025). Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.. Schizophrenia bulletin open. https://doi.org/10.1093/schizbullopen/sgaf012

Source records